Daxocox

RSS

enflicoxib

Authorised
This medicine is authorised for use in the European Union.

Overview

Daxocox is a veterinary medicine used in dogs to treat pain and inflammation associated with osteoarthritis, a condition causing swelling and pain in the joints. It contains the active substance enflicoxib.

This EPAR was last updated on 16/07/2021

Authorisation details

Product details
Name
Daxocox
Agency product number
EMEA/V/C/005354
Active substance
enflicoxib
International non-proprietary name (INN) or common name
enflicoxib
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QM01AH95
Publication details
Marketing-authorisation holder
Ecuphar NV
Date of issue of marketing authorisation valid throughout the European Union
20/04/2021
Contact address

Legeweg 157-i
B-8020 Oostkamp
Belgium

Product information

20/04/2021 Daxocox - EMEA/V/C/005354 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antiinflammatory and antirheumatic products

Therapeutic indication

For the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.

Assessment history

Related content

How useful was this page?

Add your rating